# Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Canonical URL: https://biopharmsignal.com/news/ASMB/assembly-biosciences-reports-first-quarter-2026-financial-results-and-recent-highlights
Ticker: ASMB
Company: Assembly Biosciences
Source: Assembly Biosciences
Published: 2026-05-07 20:00 EST
Original Source URL: https://investor.assemblybio.com
## Summary

– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus; Phase 2 initiation anticipated Q4 2026 – SOUTH

## Article Body
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus; Phase 2 initiation anticipated Q4 2026 – SOUTH
## Recent Company News
- 2026-05-28 20:05 EST — [Assembly Biosciences Announces Upcoming Investor Conference Presentations](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-upcoming-investor-conference-presentations) — Source: Assembly Biosciences
- 2026-05-26 20:05 EST — [Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-the-closing-of-its-offering-of-common-stock-and-pre-funded-warrants-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares) — Source: Assembly Biosciences
- 2026-05-22 11:05 EST — [Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-pricing-of-100-million-offering-of-common-stock-and-pre-funded-warrants) — Source: Assembly Biosciences
- 2026-05-22 11:00 EST — [Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-expansion-of-abi-6250-clinical-development-into-cholestatic-liver-diseases) — Source: Assembly Biosciences
- 2026-05-13 06:00 EST — [Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026](https://biopharmsignal.com/news/ASMB/assembly-biosciences-to-present-topline-phase-1a-data-on-hepatitis-delta-virus-entry-inhibitor-abi-6250-at-the-easl-congress-2026) — Source: Assembly Biosciences
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)